FDA Chemical Sensitivity Toxicology Clinicals Suggested By Coalition
This article was originally published in The Rose Sheet
Executive Summary
FDA should conduct clinical toxicity tests to determine the level of fragrance chemicals that may cause chemical sensitization in some individuals or lead to changes in the endocrine system, National Coalition for the Chemically Injured Co-President Lawrence Plumlee, MD, maintained at the FDA cosmetics stakeholders meeting in Washington D.C. Jan. 22.